Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study
Mikkael A. Sekeres,Valeria Santini,Maria Díez-Campelo,Rami S. Komrokji,Pierre Fenaux,Michael R. Savona,Yazan F. Madanat,David Valcárcel-Ferreiras,Esther Natalie Oliva,Antoine Regnault,Kristin Creel,Nishan Sengupta,Souria Dougherty,Sheetal Shah,Libo Sun,Ying Wan,Shyamala Navada,Amer M. Zeidan,Uwe Platzbecker
DOI: https://doi.org/10.1080/10428194.2024.2426057
2024-11-19
Leukemia & Lymphoma
Abstract:The authors thank all the patients and caregivers for their participation in this study and acknowledge the collaboration and commitment of all investigators and their research support staff. Writing and editorial support were provided by Jessica Deckman, PhD, CMPP, and Meredith Rogers, MS, CMPP, of The Lockwood Group (Stamford, CT, USA), funded by the Geron Corporation. MAS received consulting fees from Geron Corporation and participated in Data Safety Monitoring Board(s) or Advisory Board(s) from Bristol Myers Squibb and Kurome. VS received travel grants from Janssen and Jazz Pharmaceuticals and participated in Advisory Boards for Abbvie, Ascentage, Bristol Myers Squibb, CTI BioPharma, Geron Corporation, Gilead Sciences, Novartis, Servier, and Syros Pharmaceuticals. MDC received honorarium from Bristol Myers Squibb, Keros, and Novartis and participated in Data Safety Monitoring Board(s) or Advisory Board(s) for Agios, Astex/Otsuka, Blueprint Medicines Corporation, Bristol Myers Squibb, Curis, GlaxoSmithKline, Hemavan, Keros Therapeutics, Novartis, and Syros Pharmaceuticals. RSK received consulting fees from Geron Corporation; participated in speaker bureaus with AbbVie, CTI Biopharma, Jazz Pharmaceuticals, PharmaEssentia, and Servier; participated in Advisory Board(s) with CTI Biopharma, Jazz Pharmaceuticals, Novartis, PharmaEssentia, Rigel Pharmaceuticals, Servier, and Taiho; received honoraria from AbbVie, Bristol Myers Squibb/Celgene, CTI Biopharma, Geron Corporation, Gilead/Forty Seven, Jazz Pharmaceuticals, Novartis, PharmaEssentia, Servier, Taiho, and Takeda; received travel support from Bristol Myers Squibb/Celgene, Jazz, and PharmaEssentia; has stock and other ownership interests in AbbVie; and received research funding from Bristol Myers Squibb. PF has nothing to disclose. MRS received grants or contracts from Astex and Incyte; consulting fees from AbbVie, Bristol Myers Squibb, CTI Biopharma, Forma, Geron Corporation, GlaxoSmithKline, Rigel Pharmaceuticals, Taiho, and Treadwell; received travel grants from Astex; has patents planned, issued, or pending with Boehringer Ingelheim and Empath Biosciences; has a leadership or fiduciary role with MDSF Foundation Board of Directors; and has stock or stock options with Empath Biosciences, Karyopharm, and Ryvu. YFM received consulting fees from Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, and Kura Oncology; received travel support from Blueprint Medicines, MD Education, and Morphosys; and participated in Data Safety Monitoring Board(s) or advisory board(s) with Blueprint Medicines, Cogent Biosciences, Geron Corporation, Morphosys, Novartis, Rigel Pharmaceuticals, Sierra Oncology, Sobi, Stemline Therapeutics, and Taiho Oncology. DVF received consulting fees from Amgen, Astellas, Bristol Myers Squibb/Celgene, Jazz Pharmaceuticals, Kite/Gilead Sciences, Merck Sharpe & Dohme, Novartis, Sanofi, and Sobi Pharmaceuticals; received honorarium from Agios, Amgen, Astellas, Bristol Myers Squibb/Celgene, Gebro Pharma, Grifols, Janssen, Jazz Pharmaceuticals, Kite/Gilead Sciences, Merck Sharpe & Dohme, Novartis, Pfizer, Sanofi, and Sobi Pharmaceuticals; received travel support from Bristol Myers Squibb/Celgene, Jazz Pharmaceuticals, Novartis, and Sobi Pharmaceuticals; and participated in Data Safety Monitoring Board(s) or Advisory Board(s) for Amgen, Bristol Myers Squibb/Celgene, Grifols, Jazz Pharmaceuticals, Novartis, Servier, and Sobi Pharmaceuticals. ENO received royalties or licenses from Halia, Ryvu, and Servier; received consulting fees from Bristol Myers Squibb, Daiichi Sankyo, Inc., and Janssen; received honorarium from Amgen, Novartis, and Sobi Pharmaceuticals; received travel support from Sobi Pharmaceuticals; and participated in a Data Safety Monitoring Board(s) or Advisory Board(s) for Daiichi Sankyo, Inc., Janssen, Sanofi, and Sobi Pharmaceuticals. AR received grants or contracts from Geron Corporation. KC received consulting fees from Geron Corporation. NS, SD, SS, LS, YQ, and SN are employees of Geron Corporation. AMZ received grants or contracts from AbbVie, Amgen, Astex, Bristol Myers Squibb, Celgene, Geron Corporation, Kura Pharmaceuticals, Novartis, Otsuka, Shattuck Labs, Syros, and Takeda; and received consulting fees and honoraria from AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, Bristol Myers Squibb, BeiGene, BioCryst, Boehringer Ingelheim, Celgene, Chiesi, Daiichi Sankyo, Inc., Epizyme, Faron, Genentech, Geron Corporation, Gilead Sciences, Glycomimetics, Hikma, Janssen, Karyopharm, Keros, Kura, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel Pharma, Schrodinger, Servier, Sumitomo, Syndax, Syros, Taiho Oncology, Takeda, Treadwell, Vincerx, and Zentalis. UP received consulting fees from Abbvie, Akeso, AstraZeneca, Bristol Myers Squibb, Curis, Galapagos, Geron Corporation, Gilead Sciences, Jazz Pharmaceuticals, -Abstract Truncated-
oncology,hematology